Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.61 |
| ▸ | ST6GAL1 | P15907 | 10/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citicoline SCHEMBL25411862 | 1.00 | TSHR (0.76) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL50799 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL31554836 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL31413926 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL221081 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL19347200 | 0.96 | TSHR (0.72) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL21906414 | 0.94 | TSHR (0.70) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL667104 | 0.93 | TSHR (0.84) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL13933086 | 0.93 | P2RY2 (0.70) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL14235352 | 0.93 | P2RY2 (0.70) | TSHRGLAP2RY2ST6GAL1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205241-A1 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | SAFETY SHOT, INC. (US) | 2025-06-26 | — | — | US | claimed |
| WO-2025136556-A1 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | SAFETY SHOT, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250170246-A1 | CDP-CHOLINE A HOST-DIRECTED THERAPEUTIC FOR DISEASE CAUSED BY SARS COV-2 INFECTION | OHIO STATE INNOVATION FOUNDATION | 2025-05-29 | — | — | US | claimed |
| EP-4072336-B1 | ORAL PRODUCTS | NICOVENTURES TRADING LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | claimed |
| US-12156878-B1 | Compositions and methods for minimizing effects of alcohol intoxication | SAFETY SHOT, INC. (US) | 2024-12-03 | — | — | US | claimed |
| EP-4072301-B1 | A POUCH FOR ORAL USE COMPRISING A NANOEMULSION | NICOVENTURES TRADING LTD (GB) | 2024-11-06 | — | — | EP | claimed |
| CN-118647380-A | Treatment of autism spectrum disorders with ergothioneine or ergoselen | 自闭症治疗有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118354774-A | Parafurine-based caffeine surrogate compositions and methods of use thereof in caffeine slow metabolins | PX ING有限责任公司 | 2024-07-16 | — | — | CN | claimed |
| US-20240188613-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED | 2024-06-13 | — | — | US | claimed |
| WO-2022155669-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2022-07-21 | — | — | WO | claimed |
| US-20220211720-A1 | DIETARY SUPPLEMENT | MORRISSETTE JAMES PETER (US) | 2022-07-07 | — | — | US | claimed |
| US-11351181-B2 | Dietary supplement | KARMAGREEN, LLC | 2022-06-07 | — | — | US | claimed |
| US-11337986-B2 | Dietary supplement | KARMAGREEN, LLC | 2022-05-24 | — | — | US | claimed |
| US-20220152043-A1 | DIETARY SUPPLEMENT | MORRISSETTE JAMES PETER (US) | 2022-05-19 | — | — | US | claimed |
| US-20220152042-A1 | DIETARY SUPPLEMENT | MORRISSETTE JAMES PETER (US) | 2022-05-19 | — | — | US | claimed |
| US-11324755-B2 | Dietary supplement | KARMAGREEN, LLC | 2022-05-10 | — | — | US | claimed |
| US-11324754-B2 | Dietary supplement | KARMAGREEN, LLC | 2022-05-10 | — | — | US | claimed |
| EP-3137067-B1 | CITICOLINE TO IMPROVE MOTOR FUNCTION | KYOWA HAKKO BIO CO LTD (JP) | 2022-05-04 | — | — | EP | claimed |
| US-20220062425-A1 | LIPONUCLEOTIDE-BASED THERAPY FOR COPD | OHIO STATE INNOVATION FOUNDATION | 2022-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170246-A1 | CDP-CHOLINE A HOST-DIRECTED THERAPEUTIC FOR DISEASE CAUSED BY SARS COV-2 INFECTION | CDS2, PHOSPHO1, PCYT1A | TSHR 3893/4885GLA 2309/4885P2RY2 503/4885 |
| US-20220062425-A1 | LIPONUCLEOTIDE-BASED THERAPY FOR COPD | PHOSPHO1, CHKB, CEPT1 | TSHR 2345/4885GLA 1469/4885P2RY2 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.